Drugs / SPLIT Abs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07416552 | Jul 2026 → Feb 2034 expected | colorectal cancer | Hoffmann-La Roche | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPLIT Abs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07416552 ↗ |
| Modality | Protein / enzyme biologic | “SeParated v-domains LInkage Technology Antibodies (SPLIT Abs)” NCT07416552 ↗ |
| Route | Intravenous | “SPLIT Abs administered intravenously (IV)” NCT07416552 ↗ |